Justin Weaver

Title: Justin Weaver: Innovator in Antibody Production

Introduction

Justin Weaver is a notable inventor based in Manchester, Connecticut. He has made significant contributions to the field of biotechnology, particularly in the production of therapeutic antibodies. His work is essential in advancing medical treatments and improving patient outcomes.

Latest Patents

Justin Weaver holds a patent for "Methods of producing anti-C5 antibodies." This patent details a method for producing an anti-C5 antibody known as ravulizumab. The method involves culturing mammalian cells that contain a nucleic acid encoding the anti-C5 antibody in a specialized cell culture production medium. The process includes multiple purification steps, such as Protein A affinity chromatography, low pH viral inactivation, cation exchange chromatography, anion exchange chromatography, virus reduction filtration, and concentration and diafiltration.

Career Highlights

Justin Weaver is currently employed at Alexion Pharmaceuticals, Inc., where he continues to innovate in the field of antibody production. His expertise and dedication to research have positioned him as a valuable asset in the pharmaceutical industry.

Collaborations

Throughout his career, Justin has collaborated with talented individuals such as Hunter F. Malanson and Kyle A. Zingaro. These collaborations have fostered a productive environment for innovation and development in their respective fields.

Conclusion

Justin Weaver's contributions to the production of anti-C5 antibodies exemplify the impact of innovative thinking in biotechnology. His work not only advances scientific knowledge but also plays a crucial role in developing effective therapies for patients.